Luca Zammataro
Yale University
H-index: 32
North America-United States
Top articles of Luca Zammataro
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Erratum to: Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function (Nature,(2003), 424, 6947,(391-397), 10.1038/nature01784) | Nature | Guido Serini Donatella Valdembri Sara Zanivan Giulia Morterra Constanze Burkhardt | 2024/3/7 |
Editorial Expression of Concern: Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function | Nature | Guido Serini Donatella Valdembri Sara Zanivan Giulia Morterra Constanze Burkhardt | 2024/2/21 |
Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a Poly (adenosine diphosphate … | Gynecologic Oncology | Joan R Tymon-Rosario Paola Manara Diego D Manavella Stefania Bellone Tobias Max Philipp Hartwich | 2022/7/1 |
A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability | Cancer | Stefania Bellone Dana M Roque Eric R Siegel Natalia Buza Pei Hui | 2022/3/15 |
Novel potential oncogenic and druggable mutations of FGFRs recur in the kinase domain across cancer types | Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease | Elisabetta Grillo Cosetta Ravelli Michela Corsini Carolina Gaudenzi Luca Zammataro | 2022/2/1 |
EP007/# 994 Bay 1895344, a novel ATR inhibitor, demonstrates in vivo activity against ATRX altered uterine leiomyosarcoma | Justin Harold Diego Manavella Stefania Bellone Eric Siegel Tobias Hartwich | 2022/12/1 | |
BAY1895344, a novel ataxia telangiectasia and RAD3-related (ATR) inhibitor, is active in vivo against ATRX mutated uterine leiomyosarcoma (212) | Gynecologic Oncology | Justin Harold Diego Manavella Stefania Bellone Eric Siegel Dennis Mauricio | 2022/8/1 |
In vitro and in vivo activity of DHES0815A, an antibody-drug conjugate targeting HER2/neu in uterine serous carcinoma | Gynecologic Oncology | Joan Tymon-Rosario Elena Bonazzoli Adele Guglielmi Stefania Bellone Nupur Nagarkatti | 2021/8/1 |
Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistance | Oncogene | Mohammad Jalalirad Tufia C Haddad Jeffrey L Salisbury Derek Radisky Minzhi Zhang | 2021/4/8 |
A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics … | Annals of Oncology | S Bellone DM Roque ER Siegel N Buza P Hui | 2021/8/1 |
A novel variant of VEGFR2 identified by a pan-cancer screening of recurrent somatic mutations in the catalytic domain of tyrosine kinase receptors enhances tumor growth and … | Cancer Letters | Elisabetta Grillo Michela Corsini Cosetta Ravelli Margherita di Somma Luca Zammataro | 2021/1/1 |
Molecular Learning of a Soft-Disks Fluid | Luca Zammataro | 2021/7/24 | |
Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence | Cancer Letters | Elisabetta Grillo Michela Corsini Cosetta Ravelli Luca Zammataro Marina Bacci | 2021/6/1 |
Protein domain-based approaches for the identification and prioritization of therapeutically actionable cancer variants | Elisabetta Grillo Cosetta Ravelli Michela Corsini Luca Zammataro Stefania Mitola | 2021/12/1 | |
Inactive VEGFR2 (R1032Q) exerts pro‐oncogenic activity through heterodimerization with wild‐type receptor | The FASEB Journal | Elisabetta Grillo Cosetta Ravelli Michela Corsini Luca Zammataro Marco Presta | 2021/5 |
DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo | Gynecologic oncology | Joan Tymon-Rosario Elena Bonazzoli Stefania Bellone Aranzazu Manzano Silvia Pelligra | 2021/11/1 |
Integrated mutational landscape analysis of uterine leiomyosarcomas | Proceedings of the National Academy of Sciences | Jungmin Choi Aranzazu Manzano Weilai Dong Stefania Bellone Elena Bonazzoli | 2021/4/13 |
Preclinical activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) linked to the active metabolite of irinotecan … | Frontiers in Oncology | Emanuele Perrone Salvatore Lopez Burak Zeybek Stefania Bellone Elena Bonazzoli | 2020/2/12 |
Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas | Oncotarget | Salvatore Lopez Emanuele Perrone Stefania Bellone Elena Bonazzoli Burak Zeybek | 2020/2/2 |
In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma | Gynecologic oncology | Chanhee Han Emanuele Perrone Burak Zeybek Stefania Bellone Joan Tymon-Rosario | 2020/2/1 |
